Curriculum Vitae
Download PDFContact Information
Email: vdejvi@live.com
Phone: +31 6 40 59 39 18
Address: Van Brakelstraat 57, 3012XW, Rotterdam, The Netherlands
LinkedIn: dejvid-veizaj
Professional Experience
PhD Candidate
Oct. 2021 - Dec. 2025Leiden University Medical Center (LUMC), The Netherlands
Project goal: Rationally engineer catalytically active serine protease coagulation Factor X variants with reduced binding of small-molecule and natural inhibitors for therapeutic purposes
- • Sole computational scientist in a predominantly experimental group, translating complex simulation results for clinicians and experimentalists.
- • Analyzed experimental Factor X-small molecule inhibitor structures from the Protein Data Bank; generated additional complexes using molecular docking (HADDOCK, Schrödinger Glide) where structures were unavailable.
- • Prepared using Schrödinger Suite or AmberTools and simulated protein-ligand systems using AMBER, and/or Desmond.
- • Performed extensive molecular dynamics trajectory analyses, including RMSD/RMSF, protein–ligand interaction profiling, and binding free-energy calculations (MM/PBSA, MM/GBSA).
- • Performed per-residue free-energy decomposition to identify mutations that selectively weakened inhibitor binding, followed by targeted simulations of prioritized variants.
- • Modeled Factor X–natural inhibitor complexes using AlphaFold-Multimer, generating and refining multiple binding configurations via molecular dynamics simulations.
- • Identified interaction hotspots governing natural inhibitor binding; provided new detailed insight of their interactions and guided the design of inhibitor-resistant variants.
- • Developed a computational pipeline to assess the enzymatic competence of engineered variants despite overlapping substrate and inhibitor binding sites (currently under revision at the Journal of Chemical Information and Modeling).
- • Conducted all data analysis using Python, R, and GraphPad Prism; managed large-scale simulations via Bash scripting and Slurm job scheduling on HPC systems.
- • Generated appealing visual representations using PyMol and VMD.
- • Initiated and maintained external collaborations with researchers at Vrije Universiteit Amsterdam and the University of Basel.
- • Delivered regular presentations, posters, and oral talks, contributing to award-winning interdisciplinary conference presentations and funded grants.
- • PhD representative for the Dutch Association of Thrombosis and Haemostasis and LUMC.
- • Designed a project and supervised MSc student; taught and mentored MSc Biomedical Sciences students.
Education
Master of Drug Innovation
2019-2021Utrecht University
GPA: 7.33/10
- • Minor internship: "Engineering Factor Xa variants with lower Apixaban binding"
- • Major internship: "Resistance of Streptococcus suis against antimicrobial peptides"
- • Thesis: "Current modelling approaches to generate 3D structures of protein-oligosaccharide complexes"
- • Courses: Introduction to Python and R for Life Sciences, Design of anti-infective drug (through molecular modelling)
Bachelor of Pharmacy
2016-2019Utrecht University
GPA: 7.2/10 | Finished with Honors Degree
Relevant Experiences
Machine Learning Training & Project Experience
- • Completed Introduction to Machine Learning in Coursera.
- • Developed predictive models for protein abundance in mouse kidney tissue using curated multi-species datasets at Roche PMDA Summer School 2025.
- • Trained and evaluated multiple models (multilayer perceptrons, XGBoost, ridge regression, and random forest) to outperform linear regression.
Presentations
- • European Congress of Thrombosis and Haemostasis | October 2025
- • 15th Rembrandt Symposium, Noordwijkerhout, Netherlands | November 2024
- • International Society on Thrombosis & Haemostasis | July 2022, June 2024
- • Netherlands Society of Thrombosis & Haemostasis | March 2022, 2023, 2024
- • Netherlands society on Biomolecular Modelling Fall meeting | June 2022
- • BioExcel Summer School on Biomolecular Simulations | October 2022
Awards
- • Leiden University Fund | Travel grant
- • Dutch Society for Thrombosis & Hemostasis | Abstract Achievement Award
- • 15th Rembrandt Symposium | Best Pitch Award
- • Simons Foundation Fund | Travel Grant
- • Dutch Foundation for the Advancement of Biochemistry | Travel Grant
Publications
Peer-Reviewed Publications
VEIZAJ, D., et al. (2023). Russell's viper venom: From diagnostic to bypassing agent for hemophilia? Journal of Thrombosis and Haemostasis, 21(6), 1429–1431. https://doi.org/10.1016/j.jtha.2023.02.026
Schreuder, M., Jourdi, G., VEIZAJ, D., et al. (2024). Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors. Journal of Thrombosis and Haemostasis, 22(8), 2211–2226. https://doi.org/10.1016/j.jtha.2024.04.022
Strijbis, V.J.F., Cheung, K.L., VEIZAJ, D., et al. (2025). Modifications of the prothrombin active-site S4 subpocket confer resistance to dabigatran. Thrombosis and Haemostasis (Preprint). https://doi.org/10.1055/a-2537-6037
Bos, M.H.A., VEIZAJ, D., van 't Veer, C., & Reitsma, P.H. (2025). Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In Williams Hematology, 11th ed. (Accepted).
Manuscripts in Preparation / Submitted (Expected 2026)
VEIZAJ, D., van Diest, R., Poole III, D.A., Cheung, K.L., Reitsma, P.H., Verhoef, D., Geerke, D.P., & Bos, M.H.A. In silico modeling of factor Xa–prothrombin complexes using AlphaFold-Multimer and molecular dynamics simulations for functional prediction.
VEIZAJ, D., Smiesko, M., & Bos, M.H.A. Computational characterization of factor Xa inhibition by rivaroxaban, apixaban, and edoxaban.